SUMMARYPurpose: Double-blind randomized trial to assess efficacy and tolerability of once-daily extendedrelease levetiracetam (LEV XR) tablets (2 · 500 mg) as add-on therapy in patients (12-70 years old) with partial-onset seizures (POS) refractory to one to three antiepileptic drugs. Methods: After an 8-week prospective baselineperiod, eligible patients were randomized (1:1) to once-daily LEV XR 1,000 mg/day or placebo for 12 weeks. Evaluations included changes from baseline in POS-frequency/week, responders ( ‡50% reduction in POS-frequency/week), seizurefreedom, adverse events, laboratory tests, physical and neurologic examinations, vital signs, body-weight, and 12-lead electrocardiogram. Results: Of 188 patients screened, 158 were randomized (intention-to-treat population): LEV XR (n = 79) or placebo (n = 79). Seventy-one (89.9% %) LEV XR and 72 (91.1% %) placebo patients completed the trial. Median POS-frequency/week reduction was 46.1% % on LEV XR and 33.4% on placebo. Estimated reduction with LEV XR over placebo was 14.4% (p = 0.038). Thirty-four (43%) LEV XR and 23 (29.1% %) placebo patients experienced ‡50% % reduction in POS-frequency/week. Eight (10.1% %) patients receiving LEV XR and one (1.3% %) receiving placebo were free of POS during the 12-week treatment period. Forty-one (53.2% %) LEV XR and 43 (54.4% %) placebo patients reported ‡1 adverse event. Adverse events reported with an incidence >5% % and seen more often with LEV XR than with placebo were somnolence, influenza, irritability, nasopharyngitis, dizziness, and nausea. Discussion: Once-daily LEV XR 1,000 mg was effective and well-tolerated as adjunct therapy in patients with POS. Ten percent of patients randomized to LEV XR experienced freedom from POS. These results support the clinical value of this new LEV XR formulation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.